Reconfirmation of Regulatory Status for Europe's First G-CSF Biosimilar

The European Medicines Agency (EMA) has approved the 20th revision (Revision 20) of the marketing authorization for Tevagrastim (active ingredient: filgrastim), a treatment for neutropenia by Teva Pharmaceutical Industries (TEVA), reaffirming its validity. Tevagrastim was the first granulocyte colony-stimulating factor (G-CSF) biosimilar approved in the European Union (EU) in September 2008, demonstrating equivalence to Amgen's original Neupogen. This renewal is a post-marketing surveillance procedure that enables Teva to firmly maintain its distribution rights and regulatory compliance across Europe. It indicates that the product has consistently met strict European pharmacovigilance standards throughout its long supply history.

Demonstrating Clinical Essentiality for Patients Undergoing Cytotoxic Chemotherapy

The active ingredient of Tevagrastim, filgrastim, is a granulocyte colony-stimulating factor (r-metHuG-CSF) produced via recombinant DNA technology that promotes neutrophil production in the bone marrow. At the time of authorization, a Phase 3 clinical trial involving 348 breast cancer patients showed that the Tevagrastim group recorded an average duration of severe neutropenia of 1.1 days, demonstrating efficacy equivalent to Neupogen (1.1 days) and a clear improvement over the placebo group (3.8 days). It is used not only for chemotherapy but also as a standard treatment to reduce the risk of infection in patients undergoing hematopoietic stem cell transplantation and those with advanced HIV. Its clinical value has been reaffirmed as an essential adjunctive therapy to prevent fatal febrile neutropenia occurring during anticancer treatment.

Defending Market Share in the $6.5 Billion G-CSF Market

The global G-CSF market is currently valued between approximately $6.5 billion and $9.5 billion, with the short-acting filgrastim market accounting for about $2.5 billion to $3.5 billion. In the European biosimilar market, several drugs compete, including Sandoz's Zarzio, Pfizer's Nivestim, and Accord's Accofil. Amidst this intense environment, Teva is defending prescription confidence based on over 15 years of accumulated real-world evidence (RWE). In the European tender market, where there is significant pressure for price reductions, regulatory maintenance approval is a key requirement for maintaining a stable supply chain.

Regulatory Metrics Ensuring Manufacturing Process and Supply Chain Reliability

Because even minor changes in the manufacturing process of biologics can trigger immunogenicity issues, periodic regulatory updates are essential. This 20th revision demonstrates that the quality control at the manufacturing site in Radebeul, Germany (Teva GmbH) meets the EMA's Good Manufacturing Practice (GMP) standards. Teva can protect the stable cash flow generated from its existing product portfolio and leverage synergies with its follow-on Pegfilgrastim. Ultimately, this approval is a regulatory achievement that guarantees the sustainable profitability and supply stability of the commercialized biosimilar.